SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 8, 2015
Aduro Biotech, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
626 Bancroft Way, 3C
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (510) 848-4400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Item 7.01||Regulation FD Disclosure|
In light of the U.S. Food and Drug Administrations (the FDA) recent decision to place another companys attenuated listeria-based therapy on clinical hold, Aduro Biotech, Inc. (the Company) confirmed today that ongoing clinical trials of its Live, Attenuated, Double-Deleted, or LADD, Listeria monocytogenes immunotherapy products, in multiple cancer indications, all continue as planned. The Company also confirmed that with respect to its clinical trials, it has complied with all reporting obligations to the FDA, including those relating to safety and adverse events.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: October 8, 2015||ADURO BIOTECH, INC.|
|Executive Vice President and General Counsel|